Article Text

Download PDFPDF

Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis
  1. Julien Freitag1,2,3,
  2. James Wickham1,
  3. Kiran Shah3 and
  4. Abi Tenen2,3,4,5
  1. 1 School of Biomedical Science, Charles Sturt University, Orange, New South Wales, Australia
  2. 2 Melbourne Stem Cell Centre, Box Hill North, Victoria, Australia
  3. 3 Magellan Stem Cells, Box Hill North, Victoria, Australia
  4. 4 Monash University School of Primary Health Care, Monash University, Notting Hill, Victoria, Australia
  5. 5 Vision Eye Institute, Melbourne, Victoria, Australia
  1. Correspondence to Associate Professor Julien Freitag, julien.freitag{at}


The aim of this case report is to evaluate the efficacy of mesenchymal stem cell (MSC) therapy in the treatment of small joint osteoarthritis (OA). Acromio-clavicular (AC) joint OA is an under-diagnosed and yet frequent source of shoulder pain. MSCs have shown evidence of benefit in the treatment of knee OA. This is the first report to describe the use of MSC therapy in OA of the upper limb. A 43-year-old patient presents with painful AC joint OA and undergoes MSC therapy. The patient reported pain and functional improvement as assessed by the Disability of Arm, Shoulder and Hand Score and Numeric Pain Rating Scale. Imaging at 12 months showed structural improvement with reduction in subchondral oedema, synovitis and subchondral cysts. This case is the first to show the benefit of MSC therapy in the treatment of small joint arthropathy and also of the upper limb.

Trial registration number: Australian New Zealand Clinical Trials Registry (ACTRN12617000638336).

  • orthopaedics
  • osteoarthritis
  • sports and exercise medicine

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

View Full Text

Statistics from


  • Contributors JF is a Sport and Exercise Medicine Physician and the treating physician of the patient presented in the case report. JF, JW, KS and AT were involved in the data acquisition, analysis of data and drafting of the report. JF, JW, KS and AT have read and approved the final manuscript. JF, JW, KS and AT agreed to be accountable for the article and to ensure that all questions regarding the integrity of the article are investigated and resolved.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests JF is affiliated with Magellan Stem Cells and is a member of Magellan Stem Cells Clinical and Scientific Advisory Board. KS is affiliated with Magellan Stem Cells and is the Chief Scientific Officer of Magellan Stem Cells. AT is affiliated with Magellan Stem Cells.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.